Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11736

    +

    P2.10-044 - Impact of comorbidities on survival in elderly patients with non small cell lung cancer. (ID 2808)

    09:30 - 09:30  |  Author(s): O. Altundag
    • Abstract

    Background
    Lung cancer comprises 14% of all cancers and 29% of cancer related deaths. Mean age at diagnosis is 60, therefore it’s a disease of elderly. Comorbidities are common in this group of age. Comorbidities can affect survival, quality of life, and patients’ tolerability for therapy, as well. Nevertheless, data on the effects of comorbidities over lung cancer are limited. What we aimed with this study is to use Charlson comorbidity index (CCI) in order to define and stratify the comorbidities of our elderly patients (i.e ≥65 years) with non small cell lung cancer (NSCLC) and analyze its effect over disease-free survival (DFS) and overall survival (OS).

    Methods
    154 patients with NSCLC aged 65 and over were included in this study. Data were retrospectively collected from patients’ files. Patients’ comorbidities were classified using CCI and its effect on DFS and OS along with other prognostic factors were evaluated.

    Results
    Mean age of patients for diagnosis in this study was 70 years. Thirty patients (19,4%) had stage I disease, 17 (11%) had stage II, 46 (29,9%) had stage III, and 61 (39,6%) had stage IV disease. Fifty patients had at least one comorbid disease (min; 0 max; 6). CCI scores of the patients were as follows ; 22 patients (14,2 %) had 0 point, 59 patients (38,3 %) had 1 point, 39 patients (25,3 %) had 2 points, 22 patients (14,3%) had 3 points, 8 patients (5,2%) had 4 points, 3 patients (1,9%) had 5 points and 1 patient (0,6%) had 6 points. When patients were classified into 2 groups according to CCI scores (Group 1; CCI 0 and 1, group 2; CCI≥2), DFS of group 1 and group 2 were 13,2 and 16,9 months respectively, and OS were 21,9, and 23,1 months respectively. There was no statistically significant difference between 2 groups (p>0,1 for all comparisons). Survival rates were also similar when compared according to age-adjusted CCI scores of the two groups. The only significant predictors of both dfs and os were disease stage, Eastern Cooperative Oncology Group (ECOG) performance status and the presence of weight loss in multivariate Cox regression analysis.

    Conclusion
    In conclusion, comorbid diseases stratified according to the CCI were found not to be associated with DFS or OS in elderly patients with NSCLC in our study. The only predictive factors of survival were performance status, weight loss and disease stage. Negative results may be due to low validity of the CCI score in NSCLC, underreporting of comorbidities in patient files or aggressive biology of NSCLC which overrides comorbidities being the most imortant predictor of survival. Prospective studies with larger number of patients are needed to clarify these points.

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12631

    +

    P3.10-039 - Impact of Xanthine oxidoreductase and BRCA1 on prognosis of advanced Non-small cell Lung cancer (ID 2222)

    09:30 - 09:30  |  Author(s): O. Altundag
    • Abstract

    Background
    Lung cancer is the leading cause of cancer-related deaths over the world. Treatment in locally advanced non small cell lung cancer (NSCLC) is heterogeneous. The cure rate after complate surgical resections not good as expected. Additional treatment have come into question. Cisplatin based chemotherapy adjuvant or neoadjuvant increases overall survival in stage III NSCLC. The better understanding of the biology of NSCLC, may allow selection of appropriate treatment. Only a few research is made about prognostic value of xanthine oxidoreductase (XOR) and BRCA-1 in lung cancer.

    Methods
    In our study, stage IIIA and stage IIIB 35 patients who had been followed in Baskent Universty medical oncology and of thoracic surgery departments, operated in Baskent Ankara and Adana hospitals, and who received neoadjuvant chemotherapy were included. Clinical and histopatological parameters (age, gender, stage, smoking history, performans status, neoadjuvant chemotherapy) along with immunohistochemical BRCA1and XOR staining were examinated and corelated with survival.

    Results
    Median overall survival time was 38.5 months and 5 year survival rate was 33% Patients with ECOG PS 0 had better overall survival than the patients with ECOG PS 2 (p= 0.004) According to results of the analyses for overall survival BRCA1 positivity was significant P=0.047, XOR was 0.039. The only significant associated parameter with overall survival was ECOG PS. There was no significant relation between overall survival and XOR expression in our patients.

    Conclusion
    BRCA1 positivity was associated with shorter overall survival in stage III lung cancer in patients to whom neoadjuvant platinium based chemotherapy was given.